Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation

Blood

Volumn 114, Issue 3, 2009, Pages 608-618

  Naderi, Elin Hallan ^a   Findley, Harry W ^b   Ruud, Ellen ^c   Blomhoff, Heidi Kiil ^a   Naderi, Soheil ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ATM PROTEIN; CASPASE; CHECKPOINT KINASE 2; CISPLATIN; CYCLIC AMP; DAUNORUBICIN; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LYMPHOID CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; BIOSYNTHESIS; CELL CYCLE; DRUG EFFECT; METABOLISM; PATHOLOGY; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CYCLIC AMP; DNA DAMAGE; HUMANS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RADIATION, IONIZING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70149116197     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-204883     Document Type: Article

References (54)

1. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157-2165. (Pubitemid 46536647)
2. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet. 1993;66:83-92.
3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
4. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302:1036-1038. (Pubitemid 37386194)
5. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4:321-328. (Pubitemid 37329796)
6. Erlacher M, Michalak EM, Kelly PN, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood. 2005;106:4131-4138. (Pubitemid 41775918)
7. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 2006;13:1017-1026.
8. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal. 2002;14:1-9. (Pubitemid 34020823)
9. Ledbetter JA, Parsons M, Martin PJ, et al. Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol. 1986;137:3299-3305. (Pubitemid 17181705)
10. Kvanta A, Gerwins P, Jondal M, Fredholm BB. Stimulation of T-cells with OKT3 antibodies increases forskolin binding and cyclic AMP accumulation. Cell Signal. 1990;2:461-470. (Pubitemid 20342255)
11. Aandahl EM, Aukrust P, Skalhegg BS, et al. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J. 1998;12:855-862. (Pubitemid 28294675)
12. Rahmouni S, Aandahl EM, Trebak M, et al. Increased cAMP levels and protein kinase (PKA) type I activation in CD4+ T cells and B cells contribute to retrovirus-induced immunodeficiency of mice (MAIDS): a useful in vivo model for drug testing. FASEB J. 2001;15:1466-1468.
13. Johnson DL, Ashmore RC, Gordon MA. Effects of beta-adrenergic agents on the murine lymphocyte response to mitogen stimulation. J Immunopharmacol. 1981;3:205-219.
14. Simkin NJ, Jelinek DF, Lipsky PE. Inhibition of human B cell responsiveness by prostaglandin E2. J Immunol. 1987;138:1074-1081. (Pubitemid 17017887)
15. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983;3:295-315.
16. Kammer GM. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today. 1988;9:222-229.
17. Blomhoff HK, Smeland EB, Beiske K, et al. Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes. J Cell Physiol. 1987;131:426-433. (Pubitemid 17113058)
18. Blomhoff HK, Blomhoff R, Stokke T, et al. cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1. J Cell Physiol. 1988;137:583-587. (Pubitemid 19006747)
19. Naderi S, Wang JY, Chen TT, Gutzkow KB, Blomhoff HK. cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA. Mol Biol Cell. 2005;16:1527-1542. (Pubitemid 40349585)
20. Rosenfeld C, Goutner A, Choquet C, et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 1977;267:841-843. (Pubitemid 8110160)
21. Skopek TR, Liber HL, Penman BW, Thilly WG. Isolation of a human lymphoblastoid line heterozygous at the thymidine kinase locus: possibility for a rapid human cell mutation assay. Biochem Biophys Res Commun. 1978;84:411-416.
22. Benjamin MB, Potter H, Yandell DW, Little JB. A system for assaying homologous recombination at the endogenous human thymidine kinase gene. Proc Natl Acad Sci U S A. 1991;88:6652-6656. (Pubitemid 21915007)
23. Levy JA, Virolainen M, Defendi V. Human lymphoblastoid lines from lymph node and spleen. Cancer. 1968;22:517-524.
24. Amundson SA, Xia F, Wolfson K, Liber HL. Different cytotoxic and mutagenic responses induced by X-rays in two human lymphoblastoid cell lines derived from a single donor. Mutat Res. 1993;286:233-241. (Pubitemid 23103829)
25. Xia F, Wang X, Wang YH, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 1995;55:12-15.
26. Little JB, Nagasawa H, Keng PC, Yu Y, Li CY. Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J Biol Chem. 1995;270:11033-11036.
27. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood. 1995;85:1608-1614.
28. Darzynkiewicz Z, Bruno S, Del BG, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795-808.
29. Ferlini C, Di Cesare S, Rainaldi G, et al. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry. 1996;24:106-115. (Pubitemid 26193935)
30. Yan SZ, Huang ZH, Andrews RK, Tang WJ. Conversion of forskolin- insensitive to forskolin-sensitive (mouse-type IX) adenylyl cyclase. Mol Pharmacol. 1998;53:182-187.
31. Sunahara RK, Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol Interv. 2002;2:168-184.
32. Shanahan MF, Morris DP, Edwards BM. [3H]forskolin: direct photoaffinity labeling of the erythrocyte D-glucose transporter. J Biol Chem. 1987;262:5978-5984.
33. Ono K, Fozzard HA, Hanck DA. A direct effect of forskolin on sodium channel bursting. Pflugers Arch. 1995;429:561-569.
34. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6:909-923. (Pubitemid 44862676)
35. Lai Z, Auger KR, Manubay CM, Copeland RA. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch Biochem Biophys. 2000;381:278-284. (Pubitemid 32260315)
36. Sakaguchi K, Saito S, Higashimoto Y, et al. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase: effect on Mdm2 binding. J Biol Chem. 2000;275:9278-9283. (Pubitemid 30185148)
37. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol. 2002;323:491-501. (Pubitemid 35283675)
38. Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008;15:1019-1029. (Pubitemid 351712606)
39. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324-1337. (Pubitemid 46328466)
40. Yakovlev AG, Di Giovanni S, Wang G, et al. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem. 2004;279:28367-28374. (Pubitemid 38900116)
41. Wang P, Yu J, Zhang L. The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci U S A. 2007;104:4054-4059. (Pubitemid 47181577)
42. Karczewski JM, Vet JA, Hessels D, Noordhoek J. p53-independent apoptosis induced by menadione in the human colon carcinoma cell line Caco-2. Ann N Y Acad Sci. 2000;915:275-278. (Pubitemid 32059391)
43. Sasaki R, Suzuki Y, Yonezawa Y, et al. DNA polymerase gamma inhibition by vitamin K3 induces mitochondria-mediated cytotoxicity in human cancer cells. Cancer Sci. 2008;99:1040-1048. (Pubitemid 351997610)
44. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127:1323-1334. (Pubitemid 44960417)
45. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656-660. (Pubitemid 46232886)
46. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661-665. (Pubitemid 46232887)
47. Garcia-Bermejo L, Perez C, Vilaboa NE, de Blas E, Aller P. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells. J Cell Sci. 1998;111:637-644. (Pubitemid 28142368)
48. Vucic V, Niciforovic A, Adzic M, Radojcic MB, Ruzdijic S. The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells. Invest New Drugs. 2008;26:309-317. (Pubitemid 351873571)
49. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 1994;79:329-339. (Pubitemid 24324922)
50. Skalhegg BS, Johansen AK, Levy FO, et al. Isozymes of cyclic AMP-dependent protein kinases (PKA) in human lymphoid cell lines: levels of endogenous cAMP influence levels of PKA subunits and growth in lymphoid cell lines. J Cell Physiol. 1998;177:85-93.
51. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol. 1995;154:1634-1643.
52. Mentz F, Merle-Beral H, Dalloul AH. Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production. Leukemia. 1999;13:78-84. (Pubitemid 29043720)
53. Mentz F, Mossalayi MD, Ouaaz F, et al. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood. 1996;88:2172-2182. (Pubitemid 26307920)
54. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematologic malignancies. Biochem J. 2006;393:21-41.